Stock LONN LONZA GROUP AG
Add to a list
To use this feature you must be a member
Log inSign up

Financials Lonza Group AG

Equities

LONN

CH0013841017

Biotechnology & Medical Research

Market Closed - Swiss Exchange
Other stock markets
 16:31:30 26/04/2024 BST 		5-day change 1st Jan Change
527.8 CHF +2.72% Intraday chart for Lonza Group AG +4.97% +49.22%
04-18 Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix... Our Logo
04-18 Lonza Finance Launches EUR1 Billion 12-Year Euro Bond DJ

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 26,224 42,255 56,574 33,615 26,273 38,063 - -
Enterprise Value (EV) 1 29,185 45,068 55,616 33,429 27,195 40,239 40,532 40,646
P/E ratio 40.8 x 48.9 x 19.3 x 27.7 x 39.8 x 42.7 x 34.2 x 28.5 x
Yield 0.78% 0.53% 0.39% 0.66% 1.13% 0.85% 0.98% 1.14%
Capitalization / Revenue 4.43 x 6.83 x 10.5 x 5.4 x 3.91 x 5.73 x 5.11 x 4.54 x
EV / Revenue 4.93 x 7.29 x 10.3 x 5.37 x 4.05 x 6.06 x 5.44 x 4.85 x
EV / EBITDA 18 x 26.1 x 33.4 x 16.8 x 13.6 x 21.6 x 18.8 x 16.2 x
EV / FCF 146 x 287 x -449 x -39.2 x -91.6 x -279 x 480 x 137 x
FCF Yield 0.69% 0.35% -0.22% -2.55% -1.09% -0.36% 0.21% 0.73%
Price to Book 4.03 x 6.2 x 5.82 x 3.18 x 2.76 x 3.97 x 3.71 x 3.42 x
Nbr of stocks (in thousands) 74,246 74,289 74,283 74,189 74,282 72,117 - -
Reference price 2 353.2 568.8 761.6 453.1 353.7 527.8 527.8 527.8
Announcement Date 21/01/20 27/01/21 26/01/22 25/01/23 26/01/24 - - -
1CHF in Million2CHF
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 5,920 6,185 5,409 6,223 6,717 6,643 7,445 8,377
EBITDA 1 1,624 1,728 1,665 1,995 1,999 1,863 2,153 2,514
EBIT 1 1,249 1,358 1,151 1,397 939 1,152 1,422 1,756
Operating Margin 21.1% 21.96% 21.28% 22.45% 13.98% 17.34% 19.1% 20.96%
Earnings before Tax (EBT) 1 849 986 760 1,448 790 1,073 1,355 1,670
Net income 1 645 869 2,944 1,215 654 903.5 1,114 1,340
Net margin 10.9% 14.05% 54.43% 19.52% 9.74% 13.6% 14.96% 15.99%
EPS 2 8.650 11.63 39.52 16.34 8.880 12.36 15.43 18.50
Free Cash Flow 1 200 157 -124 -852 -297 -144.1 84.46 296.7
FCF margin 3.38% 2.54% -2.29% -13.69% -4.42% -2.17% 1.13% 3.54%
FCF Conversion (EBITDA) 12.32% 9.09% - - - - 3.92% 11.8%
FCF Conversion (Net income) 31.01% 18.07% - - - - 7.58% 22.15%
Dividend per Share 2 2.750 3.000 3.000 3.000 4.000 4.507 5.178 6.012
Announcement Date 21/01/20 27/01/21 26/01/22 25/01/23 26/01/24 - - -
1CHF in Million2CHF
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2 2025 S1 2025 S2
Net sales 1 2,944 3,074 3,111 2,542 2,867 2,982 3,241 3,078 3,639 3,135 3,454 3,466 3,779
EBITDA 1 796 893 835 847 818 987 1,008 922 1,077 837.8 975.8 984.8 1,135
EBIT 1 606 706 652 606 545 698 699 563 376 527.2 644.4 - -
Operating Margin 20.58% 22.97% 20.96% 23.84% 19.01% 23.41% 21.57% 18.29% 10.33% 16.81% 18.66% - -
Earnings before Tax (EBT) 1 407 564 422 296 464 594 854 486 304 470.2 602.4 - -
Net income 1 346 477 392 319 2,625 492 723 410 244 389.3 495.9 - -
Net margin 11.75% 15.52% 12.6% 12.55% 91.56% 16.5% 22.31% 13.32% 6.71% 12.42% 14.36% - -
EPS 2 4.640 6.390 5.240 4.280 35.24 6.610 9.730 5.540 3.340 5.310 6.780 - -
Dividend per Share 2 - - 3.000 3.000 - - 3.000 3.500 - 4.000 - - -
Announcement Date 21/01/20 24/07/20 27/01/21 23/07/21 26/01/22 22/07/22 25/01/23 21/07/23 26/01/24 - - - -
1CHF in Million2CHF
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 2,961 2,813 - - 922 2,176 2,469 2,583
Net Cash position 1 - - 958 186 - - - -
Leverage (Debt/EBITDA) 1.823 x 1.628 x - - 0.4612 x 1.168 x 1.147 x 1.028 x
Free Cash Flow 1 200 157 -124 -852 -297 -144 84.5 297
ROE (net income / shareholders' equity) 10.1% 13.1% 35.5% 11.9% 6.52% 8.93% 10.9% 12.4%
ROA (Net income/ Total Assets) 4.65% 6.15% 19.1% 7.19% 3.82% 5.3% 6.3% 7.34%
Assets 1 13,884 14,135 15,444 16,907 17,103 17,064 17,686 18,261
Book Value Per Share 2 87.60 91.70 131.0 143.0 128.0 133.0 142.0 154.0
Cash Flow per Share 2 13.20 15.10 16.30 13.70 18.80 22.30 24.40 29.10
Capex 1 786 973 1,300 1,872 1,682 1,647 1,573 1,585
Capex / Sales 13.28% 15.73% 24.03% 30.08% 25.04% 24.79% 21.13% 18.92%
Announcement Date 21/01/20 27/01/21 26/01/22 25/01/23 26/01/24 - - -
1CHF in Million2CHF
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Lonza Group AG

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
527.8 CHF
Average target price
566 CHF
Spread / Average Target
+7.24%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-16.98% 10.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. LONN Stock
  4. Financials Lonza Group AG